News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|April 14, 2025

Evidence Supporting 2024 Guidance for Lp(a) Testing

Author(s)Nihar Desai, MD, MPH, Nathan Wong, PhD, Jeremy Wigginton, MD, MBA, FAAFP

Experts discuss the evidence supporting the National Lipid Association’s (NLA) recommendation for universal lipoprotein(a) (Lp[a]) measurement and evaluate how compelling this evidence is from a clinical perspective.

Episodes in this series

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Video content above is prompted by the following:

What evidence supported the NLA’s recommendation?
How compelling is this evidence from a clinical perspective?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

Additional Emerging HER2-Targeted Therapies in NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Addressing Care Coordination and Financial Toxicity in HER2+ Breast Cancer

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

5 experts are featured in this series

Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma

ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP

February 3rd 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Understanding Real-World MRI Utilization for ED Dizziness: Ava L. Liberman, MD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text